Company profile: CatalYm
1.1 - Company Overview
Company description
- Provider of immunotherapies for cancer, developing Visugromab (CTL-002), a monoclonal antibody targeting GDF-15 to counteract immunosuppression in the tumor microenvironment and enhance immune cell infiltration against solid tumors, and running GDFATHER-2 Phase 2 trials evaluating Visugromab with nivolumab in patients relapsed or refractory to anti-PD-1/PD-L1 therapy.
Products and services
- GDFATHER-2 Trials: Phase 2 trials evaluating visugromab in combination with nivolumab across various solid tumor indications, focusing on patients relapsed or refractory to anti-PD-1/PD-L1 therapy
- Visugromab (CTL-002): A monoclonal antibody targeting GDF-15 to counteract immunosuppression in the tumor microenvironment, enhancing immune cell infiltration and activity against solid tumors
- GDF-15 Neutralization Program: CatalYm develops translational immunotherapies by identifying GDF-15 as a central tumor microenvironment regulator and translating its neutralization into meaningful clinical responses in solid tumors
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to CatalYm
PACT Pharma
HQ: United States
Website
- Description: Provider of personalized adoptive T cell therapies designed for the eradication of solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PACT Pharma company profile →
Ikena Oncology
HQ: United States
Website
- Description: Provider of novel biomarker-driven targeted cancer therapies, advancing a pipeline focused on the Hippo and RAS signaling pathways to address cancer growth, spread, and resistance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ikena Oncology company profile →
Auron Therapeutics
HQ: United States
Website
- Description: Provider of cancer therapeutics focused on transforming malignant cells toward more normal function. Offerings include AURIGIN, an AI/ML platform to identify and target drivers of tumor cell plasticity and altered cellular states in cancer, and AUTX-703, an orally available small molecule therapy targeting KAT2A/B for small cell lung cancer, neuroendocrine prostate cancer, and acute myeloid leukemia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Auron Therapeutics company profile →
MAIA Biotechnology
HQ: United States
Website
- Description: Provider of immuno-oncology drug R&D, developing first-in-class therapies with novel mechanisms, including THIO, an investigational telomere-targeting candidate that induces immune responses in cancer cells (Phase 2 in non-small cell lung cancer), and second-generation telomere-targeting agents in early discovery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MAIA Biotechnology company profile →
Apogenix
HQ: Germany
Website
- Description: Provider of clinical-stage biopharmaceutical protein therapeutics for cancer and inflammatory diseases, including Asunercept, a fully human fusion protein for solid tumors, malignant hematological diseases, and COVID-19, and the HERA-ligand technology platform creating receptor agonists targeting TNFSF-dependent pathways; engages in partnerships with pharma, biotech, and academic institutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Apogenix company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for CatalYm
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to CatalYm
2.2 - Growth funds investing in similar companies to CatalYm
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for CatalYm
4.2 - Public trading comparable groups for CatalYm
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →